Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astra USA Naropin safety data includes 218 C-section, 220 labor and delivery patients.

Executive Summary

ASTRA USA NAROPIN DATA INCLUDE EIGHT C-SECTION, NINE L&D SAFETY STUDIES, which were presented at a Dec. 12 Anesthetic & Life Support Drugs Advisory Committee review of the neuromuscular blocker ropivacaine. Astra USA presented data from eight studies performed in 218 Cesarean section patients receiving doses up to 150 mg of ropivicaine .5% concentration and nine studies of 220 labor and delivery patients receiving .25% ropivacaine. "The Pink Sheet" (Dec. 18, 1995, p. 7) incorrectly reported that Naropin safety data for use in pregnant women were derived exclusively from animal studies.
UsernamePublicRestriction

Register

PS027472

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel